(Q39778764)

14 September 2017

title

TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species (English)

1 reference

14 September 2017

0 references

reactive oxygen species

1 reference

S Rose-John

10

0 references

author name string

A M Vahdat

1

1 reference

14 September 2017

K S Reiners

2

1 reference

14 September 2017

V L Simhadri

3

1 reference

14 September 2017

D A Eichenauer

4

1 reference

14 September 2017

B Böll

5

1 reference

14 September 2017

A Chalaris

6

1 reference

14 September 2017

V R Simhadri

7

1 reference

14 September 2017

K Wiegmann

8

1 reference

14 September 2017

H-W Krell

9

1 reference

14 September 2017

A Engert

11

1 reference

14 September 2017

E P von Strandmann

12

1 reference

14 September 2017

H P Hansen

13

1 reference

14 September 2017

publication date

5 November 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

24

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

51-57

1 reference

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Bortezomib in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Proteasome inhibition induces TNFR1 shedding from human airway epithelial (NCI-H292) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Depletion of cellular cholesterol and lipid rafts increases shedding of CD30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Hydrogen peroxide and endothelin-1 are novel activators of betacellulin ectodomain shedding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

Proteasome inhibition activates the transport and the ectodomain shedding of TNF- receptors in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

7 January 2021

Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

7 January 2021

Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

7 January 2021

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

7 January 2021

The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

7 January 2021

Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

7 January 2021

Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

7 January 2021

The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.230

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.230

1 reference

14 September 2017

1 reference